Results from a large post-marketing safety surveillance study in the Republic of Korea with a quadrivalent meningococcal CRM-conjugate vaccine in individuals aged 2 months–55 years

Results from a large post-marketing safety surveillance study in the Republic of Korea with a quadrivalent meningococcal CRM-conjugate vaccine in individuals aged 2 months–55 years

The quadrivalent meningococcal conjugate vaccine MenACWY-CRM is approved in the Republic of Korea for use in individuals from 2 months of age. This single-arm, open-label, observational, multicenter, post-marketing study (NCT01766206) assessed the safety of MenACWY-CRM vaccine administered according...

Full description

Bibliographic Details
Main Authors: Byung Wook Yoo, Hye Lim Jung, Yoon Seob Byeon, Dong Ki Han, Nak Yeong Jeong, Carlo Curina, Luca Moraschini, Sung Jin Kim, Chiranjiwi Bhusal, Michele Pellegrini, Yan Miao
Format: Article
Language:English
Published: Taylor & Francis Group 2020-06-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
safety surveillance
menacwy-crm
children
adolescents
adults
republic of korea
Online Access:http://dx.doi.org/10.1080/21645515.2019.1670125

Internet

http://dx.doi.org/10.1080/21645515.2019.1670125

Similar Items